Zentalis Pharmaceuticals (ZNTL) Shares Outstanding (Diluted Average) (2019 - 2026)

Zentalis Pharmaceuticals' Shares Outstanding (Diluted Average) history runs 8 years deep, the most recent figure standing at $70.3 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Diluted Average) fell 1.97% year-over-year to $70.3 million; the TTM figure through Mar 2026 stood at $70.3 million (down 1.97% YoY), while the FY2025 annual figure was $71.9 million, up 1.11% from the prior year.
• Shares Outstanding (Diluted Average) was $70.3 million for Q1 2026 at Zentalis Pharmaceuticals, down from $71.9 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $71.9 million in Q3 2025 to a low of $45.2 million in Q1 2022.
• Historically, Shares Outstanding (Diluted Average) has averaged $64.4 million across 5 years, with a median of $70.6 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Shares Outstanding (Diluted Average) soared 38.19% in 2023, then decreased 1.97% in 2026.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $52.9 million in 2022, then grew by 23.75% to $65.4 million in 2023, then advanced by 8.67% to $71.1 million in 2024, then climbed by 1.11% to $71.9 million in 2025, then fell by 2.23% to $70.3 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $70.3 million (Q1 2026), $71.9 million (Q4 2025), and $71.9 million (Q3 2025), per Business Quant data.